Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. [electronic resource]
Producer: 20130611Description: 411-23 p. digitalISSN:- 1365-2141
- Adult
- Aged
- Bone Marrow Diseases -- chemically induced
- Combined Modality Therapy
- Dose-Response Relationship, Drug
- Female
- Hemorrhage -- etiology
- Humans
- Injections, Subcutaneous
- Male
- Middle Aged
- Myocardial Infarction -- chemically induced
- Platelet Count
- Purpura, Thrombocytopenic, Idiopathic -- complications
- Receptors, Fc -- therapeutic use
- Recombinant Fusion Proteins -- adverse effects
- Self Administration
- Splenectomy
- Thrombocytopenia -- chemically induced
- Thrombopoietin -- adverse effects
- Thrombosis -- chemically induced
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.